北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity
作者: Zhao, Xiao-su1,2; Yan, Chen-hua1,2; Liu, Dai-hong1,2; Xu, Lan-ping1,2; Liu, Yan-rong1,2; Liu, Kai-yan1,2; Qin, Ya-zhen1,2; Wang, Yu1,2; Huang, Xiao-jun1,2
关键词: Allogeneic hematopoietic stem cell transplantation ; Wilms&prime ; tumor gene 1 ; Relapse ; Minimal residual diseases ; Flow cytometry
刊名: ANNALS OF HEMATOLOGY
发表日期: 2013-08-01
DOI: 10.1007/s00277-013-1733-1
卷: 92, 期:8, 页:1111-1119
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
关键词[WOS]: MINIMAL RESIDUAL DISEASE ; ACUTE MYELOID-LEUKEMIA ; STEM-CELL TRANSPLANTATION ; DONOR LYMPHOCYTE INFUSION ; POLYMERASE-CHAIN-REACTION ; TUMOR GENE WT1 ; ACUTE LYMPHOBLASTIC-LEUKEMIA ; PROGNOSTIC-FACTORS ; CANCER PROGRAM ; BONE-MARROW
英文摘要:

Either WT1 or leukemia-associated aberrant immune phenotypes (LAIPs) was one of the minimal residual disease (MRD) parameters used to predict leukemia relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We first evaluated the clinical value of various positive MRD standards for accurately indicating relapse based on WT1 and FCM data in adult patients with acute leukemia (AL). In total, 824 AL patients treated with allo-HSCT were enrolled in this study. We compared the sensitivity and specificity of diverse, multiple-criteria MRD prognostic standards based on WT1 and FCM assays. Higher sensitivity was achieved without a loss of specificity when MRDco+, which was defined as two consecutive WT1(0.6)+ or FCM+ or both WT1(0.6)+ and FCM+ in the same sample within a year posttransplantation, was used as the positive MRD standard. Similar results were observed, even in 484 patients who had both abnormal WT1 and LAIPs values before transplant. A multivariate analysis showed that MRDco+ was an independent risk factor for leukemia relapse after transplant in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The combined use of FCM and WT1 monitoring could distinguish between patients with low and high risks of relapse. Various positive MRD standards were useful for guiding intervention.

语种: 英语
所属项目编号: 30971292
项目资助者: National Natural Science Foundation of China ; National High-Tech R&amp ; D Program of China (863 Program) ; Ministry of Health of China ; Beijing Key Laboratory for Hematopoietic Stem Cell Transplantation
WOS记录号: WOS:000321520500012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65729
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Peking Univ, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China

Recommended Citation:
Zhao, Xiao-su,Yan, Chen-hua,Liu, Dai-hong,et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity[J]. ANNALS OF HEMATOLOGY,2013,92(8):1111-1119.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhao, Xiao-su]'s Articles
[Yan, Chen-hua]'s Articles
[Liu, Dai-hong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhao, Xiao-su]‘s Articles
[Yan, Chen-hua]‘s Articles
[Liu, Dai-hong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace